In a study by Saung et al., the administration of anti-CSF1R therapy before and after the combination of a GM-CSF-secreting pancreatic cancer vaccine with anti-PD1 resulted in increased survival and higher intratumoral infiltration of CD8 and CD4 T cells [37]. The gene discussed is CD8A; the disease is pancreatic neoplasm.